<DOC>
	<DOCNO>NCT02013128</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness Ublituximab combination Ibrutinib patient advance hematologic malignancy .</brief_summary>
	<brief_title>Ublituximab + Ibrutinib Select B-cell Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<criteria>Confirmed Mantle Cell lymphoma ( MCL ) open enrollment . The Chronic Lymphocytic Leukemia ( CLL ) enrollment arm close . Refractory relapse least 1 prior treatment regimen Eastern Cooperative Oncology Group ( ECOG ) score 0 2 Any major surgery , chemotherapy immunotherapy within last 21 day Known hepatitis B virus , hepatitis C virus HIV infection Autologous hematologic stem cell transplant within 3 month study entry . Prior Allogeneic hematologic stem cell transplant exclude . Richter 's transformation , prolymphocytic leukemia primary central nervous system lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>